Persbericht van Avita van vandaag (zie bijlage) Avita naar de Nasdaq en Recell vertoont robuuste groei in US.
AVITA Medical Announces Listing on Nasdaq
Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st
_____________________________________________________________________________
Valencia, Calif., USA, and Melbourne, Australia, 30 September, 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced that its American Depositary Shares (“ADS”) have been approved to list on the Nasdaq Capital Market (Nasdaq). Trading is to begin on Tuesday, October 1, 2019, under the ticker symbol “RCEL”.
AVITA Medical’s common stock will continue to trade uninterrupted on the Australian Stock Exchange (ASX) under the symbol “AVH.” Shareholders of AVITA Medical’s ADS previously traded on the U.S. OTC market under the symbol “AVMXY” do not need to take any action as the “AVMXY” shares will automatically move to the Nasdaq Capital Market and trade under the “RCEL” ticker symbol.
“Our listing on Nasdaq is an exciting next step for AVITA Medical. It builds on our established ASX shareholder base and provides broader access to investors in the United States and worldwide,” said Dr. Michael Perry, AVITA Medical’s Chief Executive Officer. “Following the robust uptake and adoption of our RECELL® System by U.S. burn centers, we view the trading of our American Depositary Shares on the Nasdaq as a natural extension of our growth plan.”